What is Antidote?
Established in 2010 and formerly known as TrialReach, Antidote operates at the intersection of digital health and clinical research. The company specializes in precision patient recruitment, utilizing a sophisticated blend of data-driven technology and human-centric services to bridge the gap between patients and medical trials. By maintaining an extensive partner network and deep domain expertise, Antidote addresses the persistent challenge of trial enrollment, thereby accelerating the development of life-saving therapies. Its dual presence in the US and UK markets allows it to navigate complex regulatory environments while providing scalable solutions for pharmaceutical and biotech partners.
How much funding has Antidote raised?
Antidote has raised a total of $52.1M across 5 funding rounds:
Other Financing Round
$1.2M
Series A
$3.2M
Series B
$13.5M
Private Equity
$11M
Unspecified
$23.2M
Other Financing Round (2011): $1.2M with participation from Amadeus Capital Partners
Series A (2013): $3.2M led by Octopus Ventures and Amadeus Capital Partners
Series B (2015): $13.5M supported by Octopus Ventures and Amadeus Capital Partners
Private Equity (2017): $11M featuring Smedvig Capital, Merck Global Health Innovation Fund, and Octopus Ventures
Unspecified (2021): $23.2M backed by LBO France
Key Investors in Antidote
Amadeus Capital Partners
A London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, and deep tech.
Octopus Ventures
The UK's largest provider of specialist tax-efficient investments, focusing on venture capital trusts and inheritance tax solutions to support high-growth businesses.
Merck Global Health Innovation Fund
The corporate venture arm of Merck & Co., Inc., a global healthcare leader focused on delivering innovative solutions through prescription medicines, biologic therapies, and vaccines.
What's next for Antidote?
With the infusion of its latest capital, Antidote is well-positioned to scale its digital recruitment platform and deepen its integration within the global healthcare landscape. The company's strategic focus will likely center on enhancing its data-driven matching algorithms and expanding its reach into emerging therapeutic areas. As the clinical research industry increasingly shifts toward decentralized and patient-centric models, Antidote's ability to provide high-quality, diverse patient engagement will be a key differentiator. Future growth will likely involve further international expansion and the strengthening of its technological infrastructure to meet the rising demand for efficient, transparent, and rapid clinical trial enrollment processes.
See full Antidote company page
